FDA expands use of Merck’s CAPVAXIVE for high-risk children and teens

The expanded approval covers children and teens with chronic conditions that increase vulnerability to pneumococcal infections

Moderna and Merck’s mRNA cancer vax combo shows 5-year survival in melanoma trial

An exploratory overall survival signal also leaned in favor of the combination, though the companies noted the result remains preliminary

Merck’s experimental cancer drug wins FDA breakthrough status in key lung cancer setting

The designation marks the first Breakthrough Therapy recognition for calderasib and is backed by positive results from the Phase 1 KANDLELIT-001 clinical trial

Merck’s KEYTRUDA combo wins key EU backing for bladder cancer treatment

The decision now moves to the European Commission, with a final ruling expected by the third quarter of 2026

Merck reports breakthrough Phase 3 win for sac-TMT in endometrial cancer

Merck to showcase 100+ oncology studies at 2026 ASCO meeting

Highlighting KEYTRUDA & expanding cancer pipeline

US FDA okays Merck's new once-daily HIV pill

The newly approved pill combines 100 mg of doravirine with 0.25 mg of islatravir

Merck wins FDA priority review for KEYTRUDA bladder cancer combo expansion

If approved, the move would significantly broaden the use of KEYTRUDA and KEYTRUDA QLEX in combination with Padcev

Merck bags EU nod for infant RSV protection in major public health milestone

ENFLONSIA is a long-acting monoclonal antibody designed to shield infants through a typical five-month RSV season with a single, fixed dose

FDA grants priority review to Daiichi Sankyo & Merck’s lung cancer drug application

The investigational therapy, ifinatamab deruxtecan, is a potential first-in-class B7-H3 directed DXd antibody drug conjugate discovered by Daiichi Sankyo and jointly developed with Merck